In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ADMA Biologics (ADMA - Research Report), with a price target of $4.00. The company's shares closed yesterday at $3.15.According to TipRanks, Selvaraju is an analyst with an average return of -30.5% and a 21.53% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Kezar Life Sciences, and Genmab.ADMA Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, representing a 58.73% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $6.00 price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-adma-biologics-adma?utm_source=advfn.com&utm_medium=referral